U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07584226) titled 'A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors' on April 28.
Brief Summary: This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.
Study Start Date: March 09
Study Type: INTERVENTIONAL
Condition:
NRAS Mutation
NRAS-mutant Advanced Melanoma
NRAS-mutant Solid Tumors
NRAS Q61R
NRAS Q61K
NRAS Q61L
NRAS Q61H
NRAS G12D
NRAS G13R
NRAS G13D
NRAS G12V
Intervention:
DRU...